The project will run for three years and aims to validate the use of Cellevat3d nanofiber microcarriers for large scale production of iPSCs in the OLS bioreactor including benchmarking data vs market standard processes. Fraunhofer IBMT will play an important role in designing and performing the studies through its expertise in applied stem cell research and biomedical engineering, while OLS brings knowhow in bioreactor technologies and cell culture systems.

“We are very grateful for receiving funding from Eurostar and we are looking forward to collaborating with Fraunhofer IBMT and OLS on this exciting project. Human induced pluripotent stem cells exhibit significant potential for regenerative medical treatments due to their pluripotency and proliferation capacity. However, the large-scale production required for allogeneic therapies necessitates efficient and scalable culture systems. The newly launched Cellevat3d nanofiber microcarriers product with their extremely large surface area and the three-dimensional scale-up that is fast and easy, could solve the challenges for the iPSCs large-scale production in suspension bioreactor cultures,” says Laura Chirica, CEO of Cellevate.